Genta, Inc. (GNTA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genta, Inc. (GNTA)

GNTA 2.300

+0.4%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bob zagorin who wrote (1736)	9/18/2003 12:23:03 PM
From: Jim Oravetz	Read Replies (1) of 1870

FDA Approves Genta's First Product, Ganite(TM), for the Treatment Of Cancer-Related Hypercalcemia Thursday, September 18, 2003 BERKELEY HEIGHTS, N.J., Sept. 18 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA, news) announced today that the Company received approval from the Food and Drug Administration (FDA) to market Ganite™ (gallium nitrate injection) for the treatment of cancer-related hypercalcemia that is resistant to hydration. Ganite is the first drug from the Company to receive marketing approval and will be sold exclusively by Genta's oncology sales force in the U.S. Coincident with the launch of Ganite, Genta also announced the initiation of an assistance program to facilitate patient access to Ganite treatment

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next